Thomas Ciulla MD PC

[ad_1] I have great fun & satisfaction mentoring @IU_Health residents interested in #retina & #research. Congrats to these fantastic current & prior IU residents for this recent publication on a most-feared complication of #eye surgery:https://t.co/De83FjWyks [ad_2] Source by Thomas Ciulla, MD, MBA Return to main …

[ad_1] At this year’s Retina Society meeting, our team & colleagues had numerous presentations on #retina clinical science as well as #suprachoroidal delivery of tyrosine kinase inhibitor, #genetherapy & corticosteroid. #eyes #ophthalmology #biotech #medicine #clinicalresearch #macula https://t.co/gyCPxPE17z [ad_2] Source by Thomas Ciulla, MD, MBA Return …

[ad_1] RT @1stOncology: #AuraBiosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of #AU011 in… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @PharmacDaily: Clearside Biomedical’s Oncology Licensing Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Mel… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Just co-authored this paper on integrin inhibition, a potentially important pathway for treatment of common causes of vision loss, #maculardegeneration and #diabeticretinopathy… #retina #ophthalmology #eyes #diabetes #biotech #drugdevelopment #medicine https://t.co/qI3dJQ8ya1 [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @MDMagazine: .@REGENXBIO yesterday announced the clearance of the Investigational New Drug application by the #FDA to evaluate suprachor… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @RetinalPhys: Dr. Ciulla describes a study of real-world outcomes from anti-VEGF for ME in RVO done with data from a large database of a… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.